公开(公告)号：US20140045177A1

公开(公告)日：2014-02-13

申请号：US13725273

申请日：2012-12-21

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： Pei-Shin JIANG ,  Tzu-Hui WU ,  Chia-Chun CHEN ,  Su-Jan LEE ,  Chien-An CHEN ,  Chien-Ming HSU ,  Chung-Ya LIAO ,  Yu-Yu LIN

IPC: C12Q1/68

CPC classification number: C12Q1/6858 ,  C12Q1/6827 ,  C12Q2600/156

Abstract: One embodiment of the disclosure provides a kit for detecting a mutation and/or polymorphism of a specific region in a target nucleotide sequence, including: at least one first primer consisting of a first segment and a second segment, wherein the first segment is a complementary strand of a first sequence and the second segment is a second sequence, and the 3′ end of the first segment connects to the 5′ end of the second segment; a second primer being a third sequence; at least one third primer consisting of a third segment and a fourth segment, wherein the third segment is a fourth sequence and the fourth segment is a complementary strand of a fifth sequence, and the 3′ end of the third segment connects to the 5′ end of the fourth segment; and a fourth primer being a complementary strand of a sixth sequence, wherein the specific region includes rs1799853, rs1057910, rs2108622, rs9923231 and rs9934438.

Abstract translation: 本公开的一个实施方案提供了用于检测靶核苷酸序列中特定区域的突变和/或多态性的试剂盒，其包括：至少一种由第一片段和第二片段组成的第一引物，其中第一片段是互补的 第二段是第二序列，第一段的3'端连接到第二段的5'端; 第二引物是第三序列; 至少一个第三引物由第三片段和第四片段组成，其中第三片段是第四序列，第四片段是第五序列的互补链，第三片段的3'末端连接到5' 第四段结束; 第四引物是第六序列的互补链，其中特异性区包括rs1799853，rs1057910，rs2108622，rs9923231和rs9934438。

公开(公告)号：US20240327895A1

公开(公告)日：2024-10-03

申请号：US18400228

申请日：2023-12-29

Applicant: Industrial Technology Research Institute

Inventor： Tseng-Huang LIU ,  Chien-Ming HSU ,  Chih-Hung LEE

IPC: C12Q1/6806

CPC classification number: C12Q1/6806

Abstract: A composition for stabilizing cell-free nucleic acid and/or exosomal nucleic acid in blood is provided. The composition for stabilizing cell-free nucleic acid and/or exosomal nucleic acid in blood is (a) a first composition or (b) a second composition. The first composition includes (i) an antiseptic component including an allantoin-formaldehyde condensation product; (ii) an enzyme inhibitory component including a first metal chelator and (iii) a metabolic inhibitory component including NaF or sodium azide. The second composition includes (i) an antiseptic component including an allantoin-formaldehyde condensate; (ii) an enzyme inhibiting component including a first metal chelator; (iii) a metabolic an inhibitory component including NaF or sodium azide; and (iv) an anticoagulant component including a second metal chelator.